Arbutus Biopharma (ABUS) Interest Expenses (2017 - 2026)
Arbutus Biopharma (ABUS) posted Interest Expenses of $23000.0 for Q1 2026, up 27.78% sequentially from $18000.0 in Q4 2025, and down 17.86% YoY from $28000.0 in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Interest Expenses (2017 - 2026) Analysis & Trends
Arbutus Biopharma has reported Interest Expenses for 17 years, with the latest figure at $23000.0 in Q1 2026.
- Quarterly Interest Expenses fell 17.86% year-over-year to $23000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (down 96.93% YoY) and the FY2025 annual result came in at $181.4 million, up 3.4% from the prior year.
- Interest Expenses grew to $23000.0 in Q1 2026 per ABUS's latest filing, from $18000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $509000.0 in Q4 2024 and troughed at $18000.0 in Q4 2025.
- A 5-year average of $191000.0 and a median of $168000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 178.14% in 2024, then sank 96.46% in 2025.
- Over 5 years, Interest Expenses stood at $309000.0 in 2022, then plunged by 40.78% to $183000.0 in 2023, then surged by 178.14% to $509000.0 in 2024, then tumbled by 96.46% to $18000.0 in 2025, then increased by 27.78% to $23000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $23000.0, $18000.0, and $23000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Arbutus Biopharma | 1.02 Bn | 923.36 Mn | - | 18,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18,000.00 |
| Mar 31, 2026 | 17,000.00 |
| Dec 31, 2025 | 18,000.00 |
| Sep 30, 2025 | 23,000.00 |
| Jun 30, 2025 | 28,000.00 |
| Mar 31, 2025 | 28,000.00 |
| Dec 31, 2024 | 30,000.00 |
| Sep 30, 2024 | 29,000.00 |
| Jun 30, 2024 | 34,000.00 |
| Mar 31, 2024 | 44,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 171,000.00 |
| Mar 31, 2023 | 198,000.00 |
| Dec 31, 2022 | 309,000.00 |
| Sep 30, 2022 | 429,000.00 |
| Jun 30, 2022 | 482,000.00 |
| Mar 31, 2022 | 506,000.00 |
| Dec 31, 2021 | 560,000.00 |
| Sep 30, 2021 | 762,000.00 |